Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30117084 | 0.98 | L3MBTL1 (0.46) | L3MBTL1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL40215 | 0.86 | HTR2A (0.46) | L3MBTL1RAB9AMAPTNPSR1IDO1 | |
| SCHEMBL29673193 | 0.86 | HTR2A (0.46) | L3MBTL1RAB9AMAPTNPSR1IDO1 | |
| SCHEMBL31265271 | 0.84 | ATM (0.44) | L3MBTL1IDO1HTR2AADRA1ATAAR1 | |
| SCHEMBL31265270 | 0.84 | ATM (0.44) | L3MBTL1IDO1HTR2AADRA1ATAAR1 | |
| SCHEMBL13890597 | 0.84 | ATM (0.44) | L3MBTL1IDO1HTR2AADRA1ATAAR1 | |
| SCHEMBL9886157 | 0.84 | HDAC3 (0.50) | L3MBTL1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL2637443 | 0.83 | IDO1 (0.41) | L3MBTL1RAB9AMAPTNPSR1IDO1 | |
| SCHEMBL22786911 | 0.82 | TAAR1 (0.42) | IDO1HTR2AADRA1ATAAR1ATM | |
| SCHEMBL4064597 | 0.82 | HDAC3 (0.49) | L3MBTL1RAB9AHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210155593-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | REGENACY PHARMACEUTICALS LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210155593-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | REGENACY PHARMACEUTICALS LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10858323-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | REGENACY PHARMACEUTICALS, LLC (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858323-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | REGENACY PHARMACEUTICALS, LLC (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190106392-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | ACETYLON PHARMACEUTICALS, INC. | 2019-04-11 | — | — | US | disclosed |
| US-20190106392-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | ACETYLON PHARMACEUTICALS, INC. | 2019-04-11 | — | — | US | disclosed |
| EP-3368026-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | Acetylon Pharmaceuticals, Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| US-10040769-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | REGENACY PHARMACEUTICALS, LLC (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040769-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | REGENACY PHARMACEUTICALS, LLC (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2366392-A1 | Guanidine compounds and use of same as binding partners for 5-HT5 receptors | Abbott GmbH & Co. KG (DE) | 2011-09-21 | — | — | EP | disclosed |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-12-27 | — | — | US | disclosed |
| EP-1716127-A2 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | Abbott GmbH & Co. KG (DE) | 2006-11-02 | — | — | EP | disclosed |
| EP-1318811-B1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005082871-A2 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2005-09-09 | — | — | WO | disclosed |
| EP-1318811-A4 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1318811-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6545023-B2 | For treating rheumatoid arthritis; for examle, 1-(4-(4-fluorophenyl)piperidin-1-yl),3-(2-methoxy-4 -chlorobenzylaminocarbonyl),3-isopropyl-cyclopentane | MERCK & CO., INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-04-25 | — | — | US | disclosed |
| WO-2002013824-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR1, CCRL2, CCR5 | L3MBTL1 4071/4885RAB9A 1427/4885HDAC3 956/4885 |
| US-20210155593-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | HDAC4, HDAC5, HDAC9 | L3MBTL1 3450/4885RAB9A 3722/4885HDAC3 7/4885 |
| US-10040769-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | HDAC4, HDAC5, HDAC9 | L3MBTL1 3450/4885RAB9A 3722/4885HDAC3 7/4885 |
| US-20190106392-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | HDAC4, HDAC5, HDAC9 | L3MBTL1 3450/4885RAB9A 3722/4885HDAC3 7/4885 |
| US-10858323-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | HDAC4, HDAC5, HDAC9 | L3MBTL1 3450/4885RAB9A 3722/4885HDAC3 7/4885 |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | HTR5A, GRM5, TAAR5 | L3MBTL1 2611/4885RAB9A 1420/4885HDAC3 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.